FDA Inspection 1269229 — Inner Mongolia Glint Pharmaceutical Co., Ltd.
The FDA completed an inspection of Inner Mongolia Glint Pharmaceutical Co., Ltd. on Mar 27, 2025 in Chifeng. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 27, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Chifeng (China)